Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease

Kow, Chia Siang; Hasan, Syed Shahzad

doi:10.1007/s00296-020-04715-0

Cited by 28 publications

(27 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, B-cell depletion can cause lymphopenia and hypogammaglobulinemia, and is associated with more severe COVID-19. 5 Lymphopenia is known to be associated with more severe COVID-19. 6…”

Section: Introductionmentioning

confidence: 99%

Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19

Thompson

Henderson²,

Shah

et al. 2021

Preprint

View full text Add to dashboard Cite

Convalescent plasma may benefit immunocompromised individuals with COVID-19, including those with hematologic malignancy. We evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic malignancy and COVID-19 from a multi-institutional cohort. 143 treated patients were compared to 823 untreated controls. After adjustment for potential confounding factors, convalescent plasma treatment was associated with improved 30-day mortality (hazard ratio, 0.60; 95% CI, 0.37-0.97). This association remained significant after propensity-score matching (hazard ratio, 0.52; 95% CI, 0.29-0.92). These findings suggest a potential survival benefit in the administration of convalescent plasma to patients with hematologic malignancy and COVID-19.

show abstract

Section: Introductionmentioning

confidence: 99%

Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19

Thompson

Henderson²,

Shah

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Nevertheless, this issue is controversial. Kow and Hasan [ 17 ] discussed the variety of clinical characteristics and outcomes of patients with various autoimmune diseases (rheumatoid arthritis, psoriasis) and concluded that the differences might depend on the target of the immunomodulatory treatment. In contrast, rituximab might impair the priming of antibody responses to neutralise viral replication, inducing an unfavourable clinical outcome, biologic cytokine inhibitors might diminish the cytokine storm associated with COVID-19, thereby producing less severe disease.…”

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 Pandemic on Patients with Immune Thrombocytopaenia

et al. 2021

View full text Add to dashboard Cite

Background and Objectives: The aim of this study was to determine the impact of the COVID-19 pandemic on the lives of patients with immune thrombocytopaenia (ITP) treated at our hospital. Materials and Methods: The study was conducted in the Community of Madrid, which has the highest number of COVID-19 cases in Spain. We included 143 adult patients with ITP (130 with chronic ITP, 8 with persistent ITP, and 5 with newly diagnosed ITP). We conducted a telephone survey to collect the data and created a registry. Materials and Methods: Overall, 24 patients presented symptoms suggestive of COVID-19, which was confirmed by RT-PCR in 8 cases. The cumulative incidence of confirmed SARS-CoV-2 infection was higher in the patients with ITP than in the Madrid population. There were no differences in the disease incidence or clinical course of infection in the patients treated with immunosuppressants. Almost all of the patients reported adherence to the prescribed treatment, although 49.2% of the hospital visits were either cancelled or postponed, 17.2% because of the patients’ fear of coming to the centre. Nearly half of the cohort was considered vulnerable, and 17% had been granted a dependency or disability benefit. Conclusions: COVID-19 had a major impact on the psychosocial, occupational, and quality of care of patients with ITP.

show abstract

“…On the other hand, the mortality rate of the COVID‐19 was calculated as 28% in a multicenter study. Thus, rituximab use has the potential of leading to an unfavorable disease course or outcome in patients during the COVID‐19 pandemic 7 . Safavi et al 8 studied the effect of the use of B‐cell depleting agents in the course of COVID‐19 pandemic.…”

Section: Discussionmentioning

confidence: 99%

Can rituximab be used in the treatment of pemphigus vulgaris during the COVID ‐19 pandemic?

Uzunçakmak

Özkoca

Aşkın

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Rituximab is a monoclonal antibody that targets CD20, a B‐lymphocyte antigen; that leads to a decline in the B‐cell counts for at least a year. The patients who have received rituximab treatment in the previous 5 years with the diagnosis of pemphigus group of diseases at Cerrahpaşa Medical Faculty were questioned for COVID‐19 infection. A total of 48 patients were included in this study; only one male patient had COVID‐19 infection which had a mild course. There is no significant difference in the total number of lymphocytes between patients who have received rituximab within the previous 5 years or last year. The number of lymphocytes is independent of the number of courses of rituximab treatment received. Therefore, we suggest that all pemphigus patients who have received rituximab treatment within the previous 5 years should be careful of the preventive measures against the COVID‐19 infection irrespective of the number of treatment courses or the number of years which has passed since the treatment. The disease course was mild in the only infected patient. Thus, rituximab may be used in the treatment of pemphigus vulgaris during the COVID‐19 pandemic if its use is necessary.

show abstract

Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease

Cited by 28 publications

References 8 publications

Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19

Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19

Impact of COVID-19 Pandemic on Patients with Immune Thrombocytopaenia

Can rituximab be used in the treatment of pemphigus vulgaris during the COVID ‐19 pandemic?

Contact Info

Product

Resources

About